BFRIW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BF

Volume

6

Loading chart

BF

BFRIWBiofrontera Inc. Warrants

BFRIW

Pay with—

Available Balance0.00

BF

Mkt Cap

N/A

Volume

6

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Photodynamic Therapy Market: Durable Growth with a CAGR of 8.3% Through 2035The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies are under clinical development, with challenges including limited tissue penetration and high system costs.GlobeNewswire Inc. · Jul 3, 2026

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026Biofrontera Inc., a biopharmaceutical company specializing in photodynamic therapy (PDT), announced it will report Q1 2026 financial results on May 14, 2026, followed by a conference call at 11:00 a.m. ET. The company commercializes Ameluz® with RhodoLED® lamp series for treating actinic keratosis and is conducting clinical trials to expand use to non-melanoma skin cancers and acne.GlobeNewswire Inc. · May 8, 2026

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and ExtremitiesBiofrontera completed its Phase 1 pharmacokinetic study for Ameluz® to expand treatment of actinic keratoses to neck, trunk, and extremities, with plans to submit a supplemental New Drug Application to the FDA in summer 2026.GlobeNewswire Inc. · Dec 4, 2025

Biofrontera Q2 Revenue Jumps 15%Biofrontera reported a 15% revenue increase in Q2 2025, with record Ameluz sales and strategic shifts towards a royalty model. The company is advancing clinical trials for label expansions in actinic keratosis and basal cell carcinoma treatments.The Motley Fool · Aug 14, 2025

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business UpdateBiofrontera reported Q2 2025 revenues of $9.0 million, a 15% increase from the previous year. The company restructured its relationship with Biofrontera AG, acquiring US intellectual property and securing $11 million in funding. Despite increased legal expenses, the company saw improvements in sales effectiveness and is progressing with clinical trials for Ameluz®.GlobeNewswire Inc. · Aug 13, 2025

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025Biofrontera Inc. will report Q2 2025 financial results on August 13, 2025, and has signed an agreement to acquire US assets related to Ameluz® and RhodoLED® from Biofrontera AG, backed by an $11 million investment.GlobeNewswire Inc. · Aug 4, 2025

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AGBiofrontera Inc. has received a patent for a revised formulation of its drug Ameluz, extending patent protection until 2043. The company is also in negotiations with Biofrontera AG regarding a possible combination or adjustment of their license and supply agreement.GlobeNewswire Inc. · Jun 11, 2025

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic KeratosisBiofrontera and Almirall have launched the Hats On Challenge, a social media initiative to raise awareness and support for actinic keratosis (AK), a precancerous skin condition. The challenge encourages participants to wear a hat and post on social media to support the work of The Skin Cancer Foundation and Euromelanoma.GlobeNewswire Inc. · May 1, 2025

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business UpdateBiofrontera Inc. reported record total revenues of $37.3 million for 2024, a 9.5% increase from 2023. The company's net loss for 2024 was $17.8 million, an improvement from the $20.1 million loss in 2023. Biofrontera also achieved several key milestones in its clinical development program.GlobeNewswire Inc. · Mar 21, 2025

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business UpdateBiofrontera Inc. reported a 1.5% increase in Q3 2024 revenues, with a 5.6% increase in the first 9 months of 2024. The company faced challenges from Hurricane Milton that delayed shipments, but saw positive uptake of its products and received FDA approval to increase the dosage of Ameluz®.GlobeNewswire Inc. · Nov 13, 2024

to start trading

BF

BFRIWBiofrontera Inc. Warrants

BFRIW

Pay with—

Available Balance0.00

Your PositionYou don't own any BFRIW yet.

Related Tickers

Earnings